The Impact of HIV-1 Drug Escape on the Global Treatment Landscape
- PMID: 31295424
- DOI: 10.1016/j.chom.2019.06.010
The Impact of HIV-1 Drug Escape on the Global Treatment Landscape
Abstract
The rising prevalence of HIV drug resistance (HIVDR) could threaten gains made in combating the HIV epidemic and compromise the 90-90-90 target proposed by United Nations Programme on HIV/AIDS (UNAIDS) to have achieved virological suppression in 90% of all persons receiving antiretroviral therapy (ART) by the year 2020. HIVDR has implications for the persistence of HIV, the selection of current and future ART drug regimens, and strategies of vaccine and cure development. Focusing on drug classes that are in clinical use, this Review critically summarizes what is known about the mechanisms the virus utilizes to escape drug control. Armed with this knowledge, strategies to limit the expansion of HIVDR are proposed.
Keywords: HIV; antiretroviral; drug; mechanism; resistance.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Basis of selection of first and second line highly active antiretroviral therapy for HIV/AIDS on genetic barrier to resistance: a literature review.Afr Health Sci. 2014 Sep;14(3):679-81. doi: 10.4314/ahs.v14i3.25. Afr Health Sci. 2014. PMID: 25352888 Free PMC article. Review.
-
Short Communication: High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa.AIDS Res Hum Retroviruses. 2016 Dec;32(12):1159-1162. doi: 10.1089/AID.2016.0010. Epub 2016 Aug 2. AIDS Res Hum Retroviruses. 2016. PMID: 27342228
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Clinical management of HIV-1 resistance.Antiviral Res. 2010 Jan;85(1):245-65. doi: 10.1016/j.antiviral.2009.09.015. Epub 2009 Oct 4. Antiviral Res. 2010. PMID: 19808056 Review.
-
Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites.Trop Med Int Health. 2010 Nov;15(11):1357-63. doi: 10.1111/j.1365-3156.2010.02621.x. Epub 2010 Sep 25. Trop Med Int Health. 2010. PMID: 20868414 Clinical Trial.
Cited by
-
Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1.PLoS One. 2024 Mar 8;19(3):e0298542. doi: 10.1371/journal.pone.0298542. eCollection 2024. PLoS One. 2024. PMID: 38457474 Free PMC article.
-
Antiviral compounds modulate elasticity, strength and material fatigue of a virus capsid framework.Biophys J. 2022 Mar 15;121(6):919-931. doi: 10.1016/j.bpj.2022.02.014. Epub 2022 Feb 11. Biophys J. 2022. PMID: 35151634 Free PMC article.
-
Enzyme Therapy: Current Challenges and Future Perspectives.Int J Mol Sci. 2021 Aug 25;22(17):9181. doi: 10.3390/ijms22179181. Int J Mol Sci. 2021. PMID: 34502086 Free PMC article. Review.
-
Mapping Transmission Dynamics and Drug Resistance Surveillance in the Cyprus HIV-1 Epidemic (2017-2021).Viruses. 2024 Sep 11;16(9):1449. doi: 10.3390/v16091449. Viruses. 2024. PMID: 39339925 Free PMC article.
-
Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase.Nat Commun. 2020 Dec 1;11(1):5922. doi: 10.1038/s41467-020-19801-x. Nat Commun. 2020. PMID: 33262331 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
